Julia Maria Ressler

Medical University of Vienna

Austria

Research Interests

Explore related searches

Professors in Austria Professors in Immunology Immunology professors in Austria

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Collaborators (4)

Amanda Regio Pereira

Clinical lecturer

University of Sydney

AUSTRALIA

View details

Peter Petzelbauer

Medical University of Vienna

AUSTRIA

View details

Christoph Hoeller

Associate Professor, Head of Skin Cancer Center

Medical University of Vienna

AUSTRIA

View details

Martin Røssel Larsen

Professor

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Julia Maria Ressler

Research Interests

Explore related searches

Contact this professor

Articles (10)

Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function

BRAF Inhibition and UVB Light Synergistically Promote <i>Mus musculus</i> Papillomavirus 1-Induced Skin Tumorigenesis

DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma.

Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.

Regulation of the Immune Cell Repertoire in Psoriasis Patients Upon Blockade of IL-17A or TNFα

Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: a multicentre, prospective, diagnostic, clinical trial

Dabrafenib plus trametinib in unselected advanced BRAF V600–mut melanoma: a non-interventional, multicenter, prospective trial

Myofibroblast stroma differentiation in infiltrative basal cell carcinoma is accompanied by regulatory T‐cells

Real‐world outcomes using PD ‐1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Collaborators (4)

Amanda Regio Pereira

Peter Petzelbauer

Christoph Hoeller

Martin Røssel Larsen

Make your next move.